Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23607667 | 1.00 | PRMT3 (1.00) | PRMT3 | |
| SCHEMBL29360234 | 0.84 | PRMT3 (0.72) | PRMT3 | |
| SCHEMBL19860085 | 0.76 | TERT (0.64) | PRMT3 | |
| SCHEMBL19860074 | 0.75 | TERT (0.63) | PRMT3 | |
| SCHEMBL2162998 | 0.73 | IMPDH2 (1.00) | PRMT3 | |
| SCHEMBL20353575 | 0.72 | IMPDH2 (1.00) | PRMT3 | |
| SCHEMBL20353462 | 0.71 | IMPDH2 (0.78) | PRMT3 | |
| SCHEMBL30579695 | 0.71 | IMPDH2 (0.72) | PRMT3 | |
| SCHEMBL24381742 | 0.71 | PRMT3 (0.57) | PRMT3 | |
| SCHEMBL20353576 | 0.71 | IMPDH2 (0.76) | PRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| CN-117599057-A | Application of SGC707 in preparing antiarrhythmic drugs | 大连大学 | 2024-02-27 | — | — | CN | claimed |
| CN-117599056-A | Application of SGC707 in preparing anti-myocardial fibrosis medicine | 大连大学 | 2024-02-27 | — | — | CN | claimed |
| US-20220144902-A1 | METHOD FOR INDUCING MUSCULAR CELLS USING CELLS IN SPOT URINE | NIPPON SHINYAKU CO., LTD. (JP) | 2022-05-12 | — | — | US | claimed |
| US-20260000698-A1 | SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS | UNIV MINNESOTA (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-10-02 | — | — | US | disclosed |
| US-12427192-B2 | Water soluble adjuvant and composition containing same | Sumitomo Pharma Co., Ltd. (JP) | 2025-09-30 | — | — | US | disclosed |
| US-12419900-B2 | Induction of synthetic lethality with epigenetic therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| US-12383608-B2 | WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides | Sumitomo Pharma Co., Ltd. (JP) | 2025-08-12 | — | — | US | disclosed |
| US-20250152749-A1 | ASSESSMENT OF ADVERSE EVENTS INDUCED BY ADMINISTRATION OF ANTITUMOR DRUG AND/OR IMMUNE CHECKPOINT INHIBITOR BY USING DISEASE MODEL MOUSE | TOHOKU UNIVERSITY (JP) | 2025-05-15 | — | — | US | disclosed |
| EP-4540249-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | Yeda Research and Development Co. Ltd (IL) | 2025-04-23 | — | — | EP | disclosed |
| US-12281301-B2 | Sequencing-based proteomics | THE BROAD INSTITUTE, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20220241409-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2022-08-04 | — | — | US | disclosed |
| US-20220211844-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2022-07-07 | — | — | US | disclosed |
| US-20220175714-A1 | USE OF RIVASTIGMINE IN PREPARATION OF ANTI-RADIATION MEDICAMENT | SOOCHOW UNIVERSITY (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20220144902-A1 | METHOD FOR INDUCING MUSCULAR CELLS USING CELLS IN SPOT URINE | NIPPON SHINYAKU CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| CN-113456818-B | Application of PRMT3 protein and method for regulating HIV transcription | 首都医科大学附属北京儿童医院 | 2022-02-22 | — | — | CN | disclosed |
| EP-3954382-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2022-02-16 | — | — | EP | disclosed |
| EP-3949983-A1 | WATER SOLUBLE ADJUVANT | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| CN-113966326-A | Water soluble adjuvants | 大日本住友制药株式会社 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419900-B2 | Induction of synthetic lethality with epigenetic therapy | MCL1, BAD, ACIN1 | PRMT3 84/4885 |
| US-12383608-B2 | WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides | KLK3, TAP1, KLHL6 | PRMT3 3266/4885 |
| US-20220241409-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | TP53, MYD88, AQP1 | PRMT3 4391/4885 |
| US-12427192-B2 | Water soluble adjuvant and composition containing same | TP53, MYD88, AQP1 | PRMT3 4391/4885 |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | CASR, NPSR1, GSR | PRMT3 3425/4885 |
| US-20220211844-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | TP53, MYD88, AQP1 | PRMT3 4391/4885 |
| US-20260000698-A1 | SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS | NSUN2, SARS1, RNMT | PRMT3 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.